Thomas Friess

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser et al. · Blood · 2010 · 957 citations · Full text

Life Sciences, Immunology, Oncology +17

Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

Werner Scheuer, Thomas Friess, Helmut Burtscher et al. · Cancer Research · 2009 · 626 citations · Full text

Medicine, Oncology, Pharmacology +17

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models

Sylvia Herter, Frank Herting, Olaf Mundigl et al. · Molecular Cancer Therapeutics · 2013 · 359 citations

Pharmacy, Cell Biology, Immunology +17

Human pancreatic tissue concentration of bactericidal antibiotics

Markus W. Büchler, Peter Malfertheiner, Helmut Frieβ et al. · Gastroenterology · 1992 · 287 citations

Life Sciences, Microbiology, Pharmaceutics +8

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

Peter Brünker, Katharina Wartha, Thomas Friess et al. · Molecular Cancer Therapeutics · 2016 · 131 citations · Full text

Life Sciences, Cancer Biology, Cell Biology +17